

Abstract 1312

IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jorge E. Cortes¹, Elie Traer², Eunice S. Wang³, Harry P. Erba⁴, William Blum⁵, Cecilia Arana-Y⁶, Callum M. Sloss⁷, Kerry Culm-Merdek⁷, Jeanette Towles⁷, Patrick A. Zweidler-McKay⁷, and Daniel J. DeAngelo⁸
¹MD Anderson Cancer Center, Houston, TX; ²Oregon Health and Science University, Portland, OR; ³Roswell Park Cancer Institute, Buffalo, NY; ⁴University of Alabama at Birmingham, Birmingham, AL; ⁵The Ohio State University, Columbus, OH; ⁶University of New Mexico Cancer Center, Albuquerque, NM; ⁷ImmunoGen Inc., Waltham, MA; ⁸Dana-Farber Cancer Institute, Boston, MA

BACKGROUND

Acute myeloid leukemia (AML) accounts for the highest number of leukemia-related deaths. Despite standard chemotherapy options and newly approved agents, outcomes remain poor, particularly in patients unable to tolerate intense chemotherapy and stem cell transplantation.

Antibody-drug conjugates (ADCs) are engineered molecules consisting of a monoclonal antibody, directed towards tumor-associated antigens, to which cytotoxic agents are conjugated via plasma-stable linkage. In this manner, ADCs couple the targeting and pharmacokinetic features of the antibody moiety with the additional cancer-killing impact of the cytotoxic payload.

The myeloid differentiation antigen CD33 is an established therapeutic target in AML, with CD33 expression seen in greater than 90% of AML cases and clinical validation provided by the recent re-approval of the CD33-targeting ADC gemtuzumab ozogamicin (Mylotarg®). The modest activity observed with Mylotarg suggests that CD33-directed ADCs with novel mechanisms and improved safety profiles may provide additional benefit.

IMGN779: The Next Generation CD33-Targeting ADC

IMGN779 reflects the evolution of ADC design combining several key attributes:

- 1) a high-affinity, antibody-dependent cell mediated cytotoxicity (ADCC)-competent, humanized anti-CD33 antibody which is distinct from other CD33-targeting antibodies currently in clinical trials;
- 2) a cleavable s-SPDB linker which increases the preclinical maximum tolerable dose (MTD), facilitates bystander killing of nearby AML cells, and limits hepatotoxicity compared to noncleavable linkers; and
- 3) a novel DNA-alkylating payload DGN462, which when released within AML cells exerts potent antileukemia activity that results in cell cycle arrest and apoptosis, with relative sparing of normal hematopoietic progenitors.

Novel IGN payload class

DGN462 is prototypical of a novel chemical class of cytotoxic agents, known as IGNs, that consist of an indolino-benzodiazepine dimer containing a mono-imine moiety. IGNs are purpose-designed to exhibit unique DNA-alkylating activity and a high therapeutic index when compared with DNA cross-linking versions.²

First-in-human trial

Here we report early-phase findings from the dose-escalation stage of the first-in-human Phase 1 study of IMGN779 administered as monotherapy to adult AML patients with CD33-positive (CD33+) disease (NCT02674763).

Objectives, Patient Population, and Methods

Primary objectives: To establish the MTD and define the recommended Phase 2 dose (RP2D) of IMGN779 when administered as monotherapy on both once every two weeks (Q2W) and once weekly (QW) schedules

Secondary objectives: To evaluate the safety and tolerability of IMGN779 and characterize its pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity

Trial Design:

- Adult patients (≥18 years) with relapsed or refractory CD33+ AML are eligible to enroll
- CD33+ AML is defined as ≥20% of AML blasts expressing CD33 by flow cytometry
- Dose escalation follows a standard 3+3 design
- Escalation commenced with a starting dose of 0.02 mg/kg
- Treatment:**
- IMGN779 administered intravenously (IV) Q2W on Days 1 and 15 of a 28-day cycle
- IMGN779 administered IV QW on Days 1, 8, 15, and 22 of a 28-day cycle

Note: Data out for all figures 27 Oct 2017, with the exception of the bone marrow blast results (07 Nov 2017)

Dosing and Patient Allocation

Dose (mg/kg)	0.02	0.04	0.08	0.16	0.28	0.39	0.54	0.7	0.91	Total
Q2W schedule, n	3	3	3	3	5*	3	3	4*	3	30
QW schedule, n	-	-	-	-	-	6*	-	-	-	6


* patients replaced due to not completing the DLT period (not for DLT)

Based on PK/PD and safety data through 0.54 mg/kg Q2W, opening of the QW schedule was initiated at the 0.39 mg/kg dose. Enrollments on both schedules is continuing.

Demographics

Characteristic	No.	%
Patients (n = 36)*		
Age, years		
Median (range)	67 (34-81)	
Sex		
Female	20	56
Male	16	44
Race		
White	32	89
Black	2	6
Hawaiian/Pacific Islander	1	3
Other	1	3
Prior therapy		
Treatment naive	0	0
Non-intense therapy only (Aza, Dec, IDH, etc.)	10	28
Intense (7+3, HDAC, SCT, etc.)	26	72
Prior stem cell transplant	(6)	(17)
Disease status		
de novo	0	0
First relapse	9	25
Primary refractory	11	31
Relapsed refractory	16	44


Treatment-Emergent Adverse Events (TEAEs) >10%



Frequent TEAEs (N=36):

- Cytopenias: febrile neutropenia (n=13), anemia (n=5)
- Gastrointestinal: nausea (n=10), diarrhea (n=9), abdominal pain (n=6), constipation (n=5), vomiting (n=4)
- Respiratory: pneumonia (n=9), dyspnea (n=6), respiratory failure (n=5)

Grade 3+ TEAEs (>2 patients)



AEs of interest (N=36):

- Infusion reaction (n=1; related, Grade 3, no recurrence on rechallenge)
- Isolated TBili elevation (n=4; 1 related, all Grade 3)
- Isolated ALT elevation (n=1; Grade 3)

Frequent SAEs:


- Febrile neutropenia (n=13), pneumonia (n=8), respiratory failure (n=5), and bacteremia (n=4)

- DLTs:** No DLTs have been observed at doses up to 0.91 mg/kg Q2W and 0.39 mg/kg QW


- Deaths:** Five deaths occurred during the treatment period for reasons other than progressive disease; none was considered related to study drug

Pharmacokinetics and Pharmacodynamics

- Continued increases in maximal concentrations and exposure through the highest doses given to date (0.91 mg/kg Q2W)
- Increased duration of CD33 saturation with increased dosing




- Weekly dosing increases duration of saturation compared with Q2W dosing
- No substantial ADC accumulation with repeated weekly dose cohort (0.39 mg/kg QW) when compared with every other week (0.39 mg/kg Q2W)



Antileukemia Activity (≥ 0.39 mg/kg)

- Circulating blasts**
 - Sixteen of 17 patients treated at 0.39 mg/kg or above showed a decrease in peripheral blasts within 10 days after first dose (median maximal decrease 71% [16% to 100%])
- Bone marrow blasts**
 - Seven of 17 patients showed a 48%-96% reduction in bone marrow blasts. Of these 7, prior intense treatment (n=6), primary-refractory disease (n=3), mutations present: RAS (n=3), TP53 (n=2), IDH (n=2), FLT3 (n=2)
 - In addition, 1 patient treated at a lower dose (0.16 mg/kg Q2W) showed a 93% (48% to 33%) reduction in bone marrow blasts with extended treatment (Cycle 5) and continues on treatment through Cycle 14



CONCLUSIONS

These findings reflect the first-in-human clinical trial experience with a next-generation CD33-targeting ADC, IMGN779, in relapsed or refractory adult AML.

- IMGN779 displays a tolerable safety profile
- No DLTs have been observed on either administration schedule at doses examined to date
- No increase in the nature, frequency, or severity of any treatment-emergent adverse event has been observed with increasing dose
- PK exposures and PD CD33 saturation continue to increase with dose and support further escalation and exploration of QW and Q2W schedules
- Antileukemia activity was seen at doses ≥0.39 mg/kg in both schedules in seven patients with poor prognostic features (e.g. prior intense therapy, primary refractory disease, RAS/TP53/FLT3/IDH mutations)

PK, PD, and antileukemia activity alignment, along with cumulative safety, support further escalation in both schedules which is ongoing.

Pre-clinical abstract 1357

IMGN779, A Next-Generation CD33-Targeting ADC, Combines Effectively With Oyarabine in Acute Myeloid Leukemia (AML) Preclinical Models, Resulting in Increased DNA Damage Response, Cell Cycle Arrest and Apoptosis In Vitro, and Prolonged Survival In Vivo
 Saturday Dec 9, 5:30-7:30pm, GWCC – Bldg A – Hall A2

References: 1. M Miller et al. (2016) *Mol Cancer Ther* 15:1870-78; 2. S Adams et al. (2017) *22nd EHA Annual Meeting* [abstract 526]

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ASH and the author of this poster

